Quick Answer
Humacyte, Inc. reported Earnings Per Share Diluted of $0.26 (loss) per share for the year ending 2025.
- Humacyte, Inc. showed an increase of +79.4% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Humacyte, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $3.07 (loss) per share | Q1 2021: $3.46 (loss) per share | Q2 2021: $2.89 (loss) per share | Q3 2021: $0.72 (loss) per share | Q1 2022: $0.19 (loss) per share | Q2 2022: $0.35 per share | Q3 2022: $0.25 (loss) per share | Q1 2023: $0.36 (loss) per share | Q2 2023: $0.22 (loss) per share | Q3 2023: $0.25 (loss) per share | Q1 2024: $0.29 (loss) per share | Q2 2024: $0.48 (loss) per share | Q3 2024: $0.33 (loss) per share | Q1 2025: $0.28 per share | Q2 2025: $0.24 (loss) per share | Q3 2025: $0.11 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), Humacyte, Inc.'s Earnings Per Share Diluted has grown by 97.7%.
- Historical annual values: Fiscal year 2025: $0.26 (loss) per share | Fiscal year 2024: $1.26 (loss) per share | Fiscal year 2023: $1.07 (loss) per share | Fiscal year 2022: $0.12 (loss) per share | Fiscal year 2021: $0.66 (loss) per share | Fiscal year 2020: $11.54 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: